For research use only.
CAS No. 1362850-20-1
Seletalisib (UCB-5857) is a novel small-molecule inhibitor of PI3Kδ with an IC50 value of 12 nM and shows significant selectivity to PI3Kδ with respect to the other class I PI3K isoforms (between 24- and 303-fold).
Purity & Quality Control
Choose Selective PI3K Inhibitors
|Description||Seletalisib (UCB-5857) is a novel small-molecule inhibitor of PI3Kδ with an IC50 value of 12 nM and shows significant selectivity to PI3Kδ with respect to the other class I PI3K isoforms (between 24- and 303-fold).|
Seletalisib is a potent, ATP-competitive, and selective PI3Kδ inhibitor able to block protein kinase B (AKT) phosphorylation following activation of the B-cell receptor in a B-cell line. Moreover, seletalisib inhibited N-formyl peptide-stimulated but not phorbol myristate acetate–stimulated superoxide release from human neutrophils, consistent with a PI3Kδ-specific activity. Findings from cellular assays of adaptive immunity demonstrated that seletalisib blocks human T-cell production of several cytokines from activated T-cells. Additionally, seletalisib inhibited B-cell proliferation and cytokine release. In human whole blood assays, seletalisib inhibited CD69 expression upon B-cell activation and anti-IgE-mediated basophil degranulation. From 239 kinases screened, seletalisib at a concentration of 10 μM showed no inhibitory activity greater than 47% (MAP4K4) against non-PI3K kinase enzymes. Against nonkinase enzymes, seletalisib showed weak activities against phosphodiesterase (PDE)3A, PDE2A1, and PDE4D2, with inhibition varying between 32 and 74% at 10 μM. When screened at a concentration of 10 μM against 55 receptors and ion channels, the highest inhibitory activity of seletalisib observed was 20%. One receptor, neuropeptide Y receptor (Y1) showed 54% activation. In vitro receptor binding and enzyme assays across a broad range of target classes showed that seletalisib is selective for PI3Kδ. Seletalisib potently inhibited the phosphorylation of AKT following anti-IgM stimulation of the BCR on Ramos cells with an IC50 of 15 nM. When profiled in a wide range of primary cell assay systems, including fibroblasts, epithelial, endothelial and vascular smooth muscle cells, seletalisib showed significant activity only in those systems containing lymphocytes, demonstrating its functional selectivity towards PI3Kδ-expressing cells.
Seletalisib shows dose-dependent inhibition in an in vivo rat model of anti-CD3-antibody-induced interleukin 2 release. Analysis of the relationship between inhibition of IL-2 release and seletalisib blood concentration, using combined data across experiments, demonstrated that seletalisib has potent in vivo effects with an estimated IC50 value of <10 nM. In first-in-man studies, mean seletalisib plasma concentration-time profiles increased with increasing dose after single and multiple dosing, with no major deviations from dose proportionality. There was no unexpected accumulation or loss of exposure after multiple dosing (time-independent pharmacokinetic (PK) profile) and apparent t1/2 values (approx. 20h) were supportive of once-daily dosing.
In Vitro Kinase Activity Assays and Off-Target Profiling:The activities of seletalisib and the pan-PI3K inhibitor UCB1370037 were tested in biochemical kinase assays of the PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ (manufactured in-house) isoforms. Competitive time-resolved (TR) fluorescence resonance energy transfer (FRET) assays using a four-step PI3K assay reagent kit were performed. In this assay, PI3K activity is measured by the detection of phosphatidylinositol triphosphate (PIP3) as follows: A complex is formed between biotinylated PIP3 and a glutathione S-transferase (GST)-tagged pleckstrin homology–domain protein, which are detected by streptavidin-allophycocyanin (APC) and europium-labeled anti-GST antibody, respectively. Proximity of the two fluorophores results in a stable TR-FRET signal. The production of unlabeled PIP3 by PI3K in the kinase reaction results in competitive inhibition of the complex and therefore the FRET signal. Briefly, 2 μl of compound was added to wells containing 8 μl of a mixture containing phosphatidylinositol bisphosphate (PIP2) substrate and ATP, before addition of 10 μl of PI3K (prediluted to the required concentration). The final assay concentrations of ATP and PIP2 substrate were 2 μM and 10 μM, respectively. The final assay concentration of PI3K enzymes was 1–8 nM depending on batch activity. The final assay concentration of DMSO was 2.0%. The plate was incubated at room temperature for 30 minutes before addition of stop buffer and detection buffer according to manufacturer instructions, and the plate was then incubated for a further 6 hours at room temperature. TR-FRET measurements were performed on an Analyst GT plate reader. The ATP concentration dependence of the activity of seletalisib against PI3Kδ was established by running the assay in the presence of varying ATP concentrations (2, 40, 200, and 1000 μM). The final assay concentrations of PI3Kδ and PIP2 substrate in these assays were 1 nM and 25 μM, respectively.
|In vitro||DMSO||97 mg/mL (200.89 mM)|
|Ethanol||97 mg/mL (200.89 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
In vivo Formulation Calculator (Clear solution)
|Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)|
|Dosage||mg/kg||Average weight of animals||g||Dosing volume per animal||ul||Number of animals|
|Step 2: Enter the in vivo formulation ()|
|% DMSO % % Tween 80 % ddH2O|
Working concentration： mg/ml；
Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL，)
Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH2O，mix and clarify.
1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02207595||Completed||Drug: UCB5857|Other: Placebo||Healthy Volunteers||UCB Celltech|Parexel|UCB Pharma||August 2014||Phase 1|
|NCT02303509||Completed||Drug: UCB5857 Part 1|Drug: UCB5857 Part 2|Other: Placebo||Psoriasis||UCB Pharma|Parexel||August 2013||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.